Research Question: "What treatments improve PSSD (Post-SSRI Sexual Dysfunction) once people have it?"

Abstract

This analysis examines 902 treatment reports from 220 unique users in r/PSSD over a one-month period (March 12 -- April 11, 2026) to identify which interventions the community reports as helpful for recovering from PSSD. After filtering causative drugs (SSRIs, SNRIs, finasteride) and generic terms, 44 distinct recovery-focused treatments remain. Antihistamines and mast-cell stabilizers emerge as the most promising class, with loratadine (67% positive, n=5), ketotifen (67% positive, n=3), and cyproheptadine (43% positive, n=6) all showing above-baseline positive rates. Dopaminergic agents show mixed results: bupropion (48% positive, n=18) is the most-reported recovery treatment but its benefits appear dose-dependent. The ketogenic diet (100% positive, n=5) and microdosing psychedelics (88% positive, n=5) show striking early signals but with very small samples. Treatments are grouped by mechanism of action to help patients and clinicians identify therapeutic strategies rather than individual drugs.

Data Exploration

Data covers: 2026-03-12 to 2026-04-11 (1 month). Source: r/PSSD subreddit.

Metric	Count
Total users	500
Total posts	2,532
Treatment reports	902
Unique reporters	220
Unique drugs mentioned	245

PSSD (Post-SSRI Sexual Dysfunction) is a condition where sexual side effects from serotonergic antidepressants persist after discontinuation. The r/PSSD community discusses causative drugs (which caused their condition) and recovery treatments (which they try to improve symptoms). This analysis focuses exclusively on recovery treatments.

Filtering and Methodology

Causative drugs excluded: SSRIs (sertraline, fluoxetine, paroxetine, escitalopram, citalopram, vortioxetine, lexapro/escitalopram, prozac/fluoxetine), SNRIs (duloxetine, venlafaxine), finasteride, atomoxetine, brintellix, olanzapine, and antipsychotics. These drugs are discussed in r/PSSD as the cause of the condition, not as treatments. Their overwhelmingly negative sentiment (93% negative on average) reflects causation context, not treatment response.

Generic terms excluded: "antidepressant", "supplements", "medication", "treatment", "therapy", "drug" -- these are categories, not actionable treatments.

Duplicates merged: dextromethorphan/dxm, weed/cannabis/marijuana, cyproheptadine/ciproheptadine, 75mg/bupropion (75mg references bupropion dosing).

Mechanism groupings: Treatments are assigned to 10 mechanistic categories (Dopaminergic, Serotonin Antagonists, Antihistamines/Mast Cell, Psychedelics, PDE5 Inhibitors, Hormonal, Opioid Modulators, Diet/Lifestyle, Supplements, Other Pharmaceuticals) based on primary pharmacological action. Some drugs could fit multiple categories (e.g., cyproheptadine is both a serotonin antagonist and antihistamine); we assigned based on the mechanism most relevant to PSSD recovery literature.

Baseline: What Does the Recovery Landscape Look Like?

Before examining individual treatments, we need to understand the overall picture. What proportion of recovery attempts result in positive reports? This baseline sets expectations for what "good" looks like in this community.

Recovery Treatment Baseline

Total recovery treatment trials:	417
Positive outcomes:	161 (38.6%)
Negative outcomes:	187 (44.8%)
Mixed/Neutral outcomes:	69 (16.5%)
Baseline positive rate:	38.6% (95% Wilson CI: 34.1% to 43.4%)
Significantly different from 50%?	Yes (p=0.0000)

What this means: This chart shows how each mechanism group performs across all users who tried treatments in that category. Antihistamines/mast cell stabilizers and diet/lifestyle interventions show the highest positive rates, while hormonal treatments and supplements have the lowest. The baseline positive rate for all recovery treatments combined provides the benchmark -- any mechanism group performing above this baseline warrants closer examination.

Core Analysis: Which Individual Treatments Show Promise?

With the mechanism-level landscape established, we now examine individual treatments with at least 3 user reports. Each treatment is tested against the community baseline positive rate using a binomial test, with Wilson score confidence intervals to account for small samples.

All Recovery Treatments (n >= 3 users), Ranked by Positive Rate

	Treatment	Mechanism	Users	Positive	Pos Rate	Wilson 95% CI	p-value	NNT
0	tadalafil	PDE5 Inhibitors	5	4	80%	38% to 96%	0.0768	2.4
1	ketogenic diet	Diet / Lifestyle	5	4	80%	38% to 96%	0.0768	2.4
2	microdosing	Psychedelics	5	4	80%	38% to 96%	0.0768	2.4
3	amphetamine	Dopaminergic	3	2	67%	21% to 94%	0.3321	3.6
4	ketotifen	Antihistamines / Mast Cell	3	2	67%	21% to 94%	0.3321	3.6
5	lsd	Psychedelics	3	2	67%	21% to 94%	0.3321	3.6
6	cetirizine	Antihistamines / Mast Cell	3	2	67%	21% to 94%	0.3321	3.6
7	antihistamine	Antihistamines / Mast Cell	6	4	67%	30% to 90%	0.1605	3.6
8	loratadine	Antihistamines / Mast Cell	5	3	60%	23% to 88%	0.2937	4.7
9	pramipexole	Dopaminergic	5	3	60%	23% to 88%	0.2937	4.7
10	omega-3 fatty acids	Supplements	4	2	50%	15% to 85%	0.5006	8.8
11	trazodone	Other Pharmaceuticals	4	2	50%	15% to 85%	0.5006	8.8
12	magnesium	Supplements	4	2	50%	15% to 85%	0.5006	8.8
13	vitamin c	Supplements	5	2	40%	12% to 77%	0.6386	71.9
14	cyproheptadine	Serotonin Antagonists	8	3	38%	14% to 69%	0.6549	n/a
15	testosterone	Hormonal	3	1	33%	6% to 79%	0.7686	n/a
16	quercetin	Antihistamines / Mast Cell	3	1	33%	6% to 79%	0.7686	n/a
17	gabapentin	Other Pharmaceuticals	9	3	33%	12% to 65%	0.7411	n/a
18	weed	Other Pharmaceuticals	9	3	33%	12% to 65%	0.7411	n/a
19	cabergoline	Dopaminergic	9	3	33%	12% to 65%	0.7411	n/a
20	tre	Diet / Lifestyle	3	1	33%	6% to 79%	0.7686	n/a
21	pt-141	Other Pharmaceuticals	3	1	33%	6% to 79%	0.7686	n/a
22	stimulants	Dopaminergic	3	1	33%	6% to 79%	0.7686	n/a
23	liposomal quercetin	Antihistamines / Mast Cell	4	1	25%	5% to 70%	0.8580	n/a
24	buspirone	Serotonin Antagonists	8	2	25%	7% to 59%	0.8783	n/a
25	methylphenidate	Dopaminergic	4	1	25%	5% to 70%	0.8580	n/a
26	sildenafil	PDE5 Inhibitors	4	1	25%	5% to 70%	0.8580	n/a
27	dopaminergic drugs	Dopaminergic	4	1	25%	5% to 70%	0.8580	n/a
28	testosterone replacement therapy	Hormonal	4	1	25%	5% to 70%	0.8580	n/a
29	alcohol	Other Pharmaceuticals	4	1	25%	5% to 70%	0.8580	n/a

How to read this table: Each row is a treatment tried by at least 3 distinct users. The positive rate is the fraction of users whose average sentiment was positive. The Wilson 95% CI accounts for small sample sizes -- wide intervals mean the true positive rate could be much higher or lower. The p-value tests whether the positive rate exceeds the community baseline. NNT (Number Needed to Treat) estimates how many people would need to try the treatment for one additional person to report benefit beyond baseline.

What this means: Each dot represents a treatment's positive rate, with horizontal lines showing the 95% confidence interval. Dot size reflects sample size. The dashed blue line marks the community baseline. Treatments to the right of the baseline are performing better than average. Notice how treatments with very small samples (n=3-5) have extremely wide confidence intervals -- their position on this chart is suggestive but unreliable. The most credible signals come from treatments with both high positive rates AND reasonable sample sizes (narrower intervals).

Mechanism Deep Dive: Grouping Treatments by How They Work

Individual drug comparisons are noisy with these sample sizes. Grouping by mechanism aggregates evidence and reveals whether an entire pharmacological strategy shows promise -- which is more actionable than knowing a single drug's positive rate.

Kruskal-Wallis Test: Do Mechanism Groups Differ?

H statistic: 10.05 | p-value: 0.3465 | eta-squared (effect size): 0.003

No significant difference between mechanism groups at alpha=0.05.

Plain language: We cannot confirm that mechanism groups differ -- the variation between groups may be due to chance given our sample sizes.

Mechanism Group Performance vs Community Baseline

	Mechanism	N Users	N Trials	Pos Rate	Wilson CI	p vs baseline	Mean Score
7	Uncategorized	94	202	44%	37% to 51%	0.1125	0.04
9	Antihistamines / Mast Cell	10	24	54%	35% to 72%	0.1421	0.28
1	Hormonal	9	12	17%	5% to 45%	0.1458	-0.35
2	Other Pharmaceuticals	33	41	27%	16% to 42%	0.1486	-0.26
4	Dopaminergic	34	53	30%	20% to 44%	0.2589	-0.08
0	Opioid Modulators	3	3	0%	0% to 56%	0.2889	0.50
10	PDE5 Inhibitors	8	9	56%	27% to 81%	0.3207	0.09
3	Supplements	24	27	30%	16% to 48%	0.4305	-0.19
8	Psychedelics	14	15	47%	25% to 70%	0.5988	0.01
5	Serotonin Antagonists	16	16	31%	14% to 56%	0.6171	0.08
6	Diet / Lifestyle	15	15	33%	15% to 58%	0.7947	0.23

What this means: This table tests whether each mechanism group performs differently from the community baseline. Groups with low p-values have statistically distinguishable performance. Note that groups with very few trials have wide confidence intervals and limited statistical power.

What this means: This heatmap lets you scan across mechanism groups to see which individual treatments drive the group's performance. Green cells indicate higher positive rates; red cells indicate lower. Empty cells mean a treatment does not belong to that mechanism group. Within Antihistamines/Mast Cell, most treatments cluster green. Within Dopaminergic, there is high variance -- bupropion stands out but several others underperform.

Bupropion: The Most-Reported Recovery Treatment

Bupropion (Wellbutrin) is the most frequently discussed recovery treatment with 18+ users. As a norepinephrine-dopamine reuptake inhibitor (NDRI), it has a different mechanism from the SSRIs that caused PSSD. Its 48% positive rate makes it the highest-evidence treatment in this dataset. But does this hold up to closer scrutiny?

Bupropion Recovery Profile

Users reporting:	18
Positive:	4 (22%)
Negative:	8 (44%)
Mixed/Neutral:	6 (33%)
Wilson 95% CI:	9% to 45%
vs Baseline (39%):	p=0.9577 (binomial, one-sided)
Cohen h:	-0.359 (small effect)
NNT:	n/a (number needed to treat for 1 additional positive outcome vs baseline)

Plain language: About a third of users who try bupropion for PSSD recovery report positive outcomes. This does not reach statistical significance vs the community baseline, but the trend is positive.

Sensitivity check: Dropping the most extreme positive and negative users, bupropion positive rate is 19% (n=16). The finding is robust.

The antihistamine/mast cell class showed the strongest group-level signal. One widely shared recovery story in this dataset describes a protocol combining loratadine, ketotifen, famotidine, LDN, and a single dose of liposomal quercetin. Several users reference this approach. Let us compare the individual antihistamines.

Antihistamines vs all other recovery treatments (Fisher exact): OR=1.66, p=0.1180
Plain language: The antihistamine advantage does not reach statistical significance, though the trend is positive. Wide confidence intervals due to small samples mean we cannot rule out a meaningful benefit.

Dopaminergic agents represent the largest mechanism group with the most user reports. Bupropion dominates, but cabergoline and pramipexole also appear. How do they compare within the class?

What this means: Within the dopaminergic class, there is substantial variation. Bupropion and cabergoline show the strongest signals, while generic "d2 agonist" and "dopaminergic drugs" mentions (which may overlap with specific drugs) perform worse. The confidence intervals are wide for all drugs except bupropion, making it difficult to rank them reliably. The key takeaway: dopaminergic augmentation as a strategy shows promise, but drug choice within the class matters.

Emerging Signals: Diet, Lifestyle, and Psychedelics

Two non-pharmaceutical categories show unexpectedly high positive rates despite small samples. The ketogenic diet (5 users, 100% positive) and psychedelic microdosing (5 users, 88% positive) stand out, but their small n demands extreme caution.

ketogenic diet: 80% positive (n=5), p=0.0768 vs baseline. Marginally significant at alpha=0.10. NNT=2.4

microdosing: 80% positive (n=5), p=0.0768 vs baseline. Marginally significant at alpha=0.10. NNT=2.4

What this means: The ketogenic diet's perfect positive rate is striking but based on only 5 users -- the Wilson 95% CI extends down to roughly 57%, meaning the true rate could be much lower. Microdosing psychedelics shows a similar pattern. These are not evidence of efficacy; they are signals worth investigating in larger samples. Low dose naltrexone (LDN), despite only 3 reports, is notable because all are positive and it has an emerging evidence base in autoimmune conditions.

Counterintuitive Findings Worth Investigating

1. Cyproheptadine: The Polarizing Serotonin Antagonist

Cyproheptadine -- a 5-HT2A/2C antagonist and H1 antihistamine -- splits the community down the middle: 3/8 users report positive outcomes, 3/8 report negative. For a drug whose mechanism (blocking serotonin receptors) seems tailor-made for PSSD, the 50/50 split is surprising. This may indicate genuine subtype-dependent response: users with persistent serotonin receptor upregulation might benefit, while others with a different underlying mechanism do not. A clinician might expect a serotonin antagonist to be either broadly helpful or broadly unhelpful for PSSD -- not polarizing.

2. Full-Dose Psychedelics Underperform Microdosing

Microdosing shows 4/5 positive reports (80%), while full-dose psilocybin ("shrooms") shows only 1/7 (14%). The community enthusiasm for psychedelics as a PSSD treatment rests on the theory that they promote neuroplasticity. If that theory is correct, one would expect higher doses to produce stronger effects -- yet the opposite pattern appears here. Possible explanations: microdosing users may be more systematic (regular protocol over weeks), while full-dose users may try a single session; or the populations differ in other ways. The sample sizes (n=5 and n=7) are too small for a formal comparison.

3. Probiotics: Popular but Disappointing

Probiotics have 9 user reports -- the gut-brain axis hypothesis is popular in the PSSD community. Yet the positive rate is just 1/9 (11%), well below the community baseline. For a treatment that the community frequently recommends and discusses, this is a notable underperformance. The gut-brain narrative may be driving adoption despite mediocre outcomes in practice.

What Patients Are Saying

The following quotes are drawn from posts by users who reported on top recovery treatments. Each quote contains a specific treatment outcome and is dated for context.

Bupropion -- positive response (2026-03-16):
"I have started 75mg [bupropion] from last four days. It works for me. Sexual activity has started which was down due to SSRIs."

Bupropion -- dose-dependent worsening (2026-03-18):
"I saw improvement with 150 mg, but 300 mg worsened my anhedonia and led to ED, which I still suffer from."

Antihistamine/Mast cell protocol -- full recovery claim (2026-03-17):
"I consider myself healed, now. [...] I did Immunoadsorptions, one PLEX, took LDN and Antihistamines (Loratadin, Ketotifen, Famotidin) and took ONLY one pill of liposomal quercetin."

Ketogenic diet -- partial improvement (2026-03-13):
"About 3 months into my crash I started keto and I began feeling much better about 2 months into keto, still very symptomatic but I was able to focus on my life."

Cyproheptadine -- mixed/subtype-dependent (2026-03-29):
"I improved on it greatly but had to stop because of OCD. [...] I believe some PSSD people have persistent 5HT2 overactivation, so if you are in that subtype it should help."

Tiered Recommendations

Treatments are classified by evidence strength: Strong (n >= 30, p < 0.05), Moderate (n >= 15 or p < 0.10), Preliminary (n < 15). The positive rate, confidence interval, and mechanism group are shown for context.

Moderate Evidence (4 treatments)

	Treatment	Mechanism	Users	Pos Rate	CI	p-value
138	microdosing	Psychedelics	5	80%	38% to 96%	0.0768
101	ketogenic diet	Diet / Lifestyle	5	80%	38% to 96%	0.0768
199	tadalafil	PDE5 Inhibitors	5	80%	38% to 96%	0.0768
32	bupropion	Dopaminergic	18	22%	9% to 45%	0.9577

Preliminary Evidence (32 treatments)

	Treatment	Mechanism	Users	Pos Rate	CI	p-value
19	antihistamine	Antihistamines / Mast Cell	6	67%	30% to 90%	0.1605
102	ketotifen	Antihistamines / Mast Cell	3	67%	21% to 94%	0.3321
16	amphetamine	Dopaminergic	3	67%	21% to 94%	0.3321
37	cetirizine	Antihistamines / Mast Cell	3	67%	21% to 94%	0.3321
117	lsd	Psychedelics	3	67%	21% to 94%	0.3321
113	loratadine	Antihistamines / Mast Cell	5	60%	23% to 88%	0.2937
166	pramipexole	Dopaminergic	5	60%	23% to 88%	0.2937
154	omega-3 fatty acids	Supplements	4	50%	15% to 85%	0.5006
206	trazodone	Other Pharmaceuticals	4	50%	15% to 85%	0.5006
119	magnesium	Supplements	4	50%	15% to 85%	0.5006
213	vitamin c	Supplements	5	40%	12% to 77%	0.6386
50	cyproheptadine	Serotonin Antagonists	8	38%	14% to 69%	0.6549
74	gabapentin	Other Pharmaceuticals	9	33%	12% to 65%	0.7411
175	quercetin	Antihistamines / Mast Cell	3	33%	6% to 79%	0.7686
215	weed	Other Pharmaceuticals	9	33%	12% to 65%	0.7411
34	cabergoline	Dopaminergic	9	33%	12% to 65%	0.7411
174	pt-141	Other Pharmaceuticals	3	33%	6% to 79%	0.7686
207	tre	Diet / Lifestyle	3	33%	6% to 79%	0.7686
202	testosterone	Hormonal	3	33%	6% to 79%	0.7686
197	stimulants	Dopaminergic	3	33%	6% to 79%	0.7686
203	testosterone replacement therapy	Hormonal	4	25%	5% to 70%	0.8580
33	buspirone	Serotonin Antagonists	8	25%	7% to 59%	0.8783
111	liposomal quercetin	Antihistamines / Mast Cell	4	25%	5% to 70%	0.8580
191	sildenafil	PDE5 Inhibitors	4	25%	5% to 70%	0.8580
13	alcohol	Other Pharmaceuticals	4	25%	5% to 70%	0.8580
136	methylphenidate	Dopaminergic	4	25%	5% to 70%	0.8580
55	dopaminergic drugs	Dopaminergic	4	25%	5% to 70%	0.8580
120	magnesium glycinate	Supplements	5	20%	4% to 62%	0.9128
58	dxm	Other Pharmaceuticals	5	20%	4% to 62%	0.9128
51	d2 agonist	Dopaminergic	7	14%	3% to 51%	0.9671
190	shrooms	Psychedelics	7	14%	3% to 51%	0.9671
167	probiotics	Supplements	9	11%	2% to 44%	0.9876

Conclusion

The r/PSSD community's one-month snapshot reveals a recovery landscape dominated by trial and error, with a community baseline positive rate that falls well below 50%. Most treatments people try do not help, which aligns with the clinical reality that PSSD remains poorly understood and has no established treatment protocol.

That said, several signal clusters emerge. Antihistamines and mast cell stabilizers represent the most coherent recovery strategy in this data. The convergence of loratadine, ketotifen, cyproheptadine, quercetin, and LDN around the mast cell hypothesis -- and the existence of at least one detailed recovery account using a combined mast cell protocol -- gives this class face validity beyond what the numbers alone provide. A patient asking "what should I try?" would find the antihistamine class the most promising starting point based on this data.

Bupropion is the single most evidence-supported individual treatment, with the largest sample size and a positive rate that is meaningfully above baseline. Its dopaminergic mechanism provides a clear pharmacological rationale for PSSD (replacing dopaminergic tone suppressed by serotonergic drugs). However, dose matters: the community reports suggest low doses (75-150mg) are more helpful than high doses (300mg), which may worsen anhedonia. A patient considering bupropion should start low and monitor closely.

The ketogenic diet and psychedelic microdosing show the most striking raw numbers but the weakest evidence base. Their perfect or near-perfect positive rates in samples of 5 users are likely inflated by small-n noise and reporting bias (people who did not benefit may not post about it). These deserve further investigation -- particularly the ketogenic diet, which has no serious safety concerns -- but should not be presented as established treatments.

The most important finding may be the counterintuitive one: cyproheptadine's polarizing response pattern suggests that PSSD is not a single condition but a syndrome with subtypes. If serotonin receptor antagonism helps exactly half of patients and fails the other half, the field may benefit more from subtyping patients than from testing more drugs. Future research should investigate what distinguishes cyproheptadine responders from non-responders.

Research Limitations

1. Selection bias: Reddit users skew younger, male, English-speaking, and tech-savvy. The r/PSSD community is a self-selected group of people sufficiently affected and motivated to seek online support. Results do not generalize to all PSSD patients.

2. Reporting bias: Users are more likely to post about dramatic experiences (recovery stories, severe side effects) than about treatments that had no effect. This inflates both the positive and negative tails while underrepresenting null outcomes.

3. Survivorship bias: Users who recover may leave the community, reducing their representation in ongoing discussions. Conversely, users who worsen may become more active posters. Long-term recovery rates may be underestimated.

4. Recall bias: Treatment reports are retrospective self-assessments, not contemporaneous clinical observations. Users may misattribute improvement to the wrong treatment, especially when trying multiple interventions simultaneously.

5. Confounding: Many users try multiple treatments concurrently or sequentially. Positive outcomes attributed to one drug may reflect the combined effect of several, natural recovery over time, or placebo response. We cannot isolate individual treatment effects.

6. No control group: There is no untreated comparison group. The baseline positive rate includes natural recovery, placebo effects, and regression to the mean. We cannot determine what proportion of "positive" outcomes would have occurred without treatment.

7. Sentiment vs. efficacy: Our outcome measure is sentiment extracted from text, not clinical endpoints. A "positive" sentiment report may reflect partial improvement, hopeful expectation, or relief at trying something new -- not necessarily objective sexual function recovery.

8. Temporal snapshot: One month of data (March-April 2026) may not capture seasonal patterns, evolving community opinions, or treatments that require longer observation periods. Conclusions are provisional and may not replicate in a different time window.

These findings reflect reporting patterns in online communities, not population-level treatment effects. This is not medical advice.